NCT00103831已完成1 期
Phase I Alimta Combination With BMS-275183 (Oral Taxane)
Bristol-Myers Squibb3 个研究点 分布在 2 个国家开始时间: 2005年2月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 3
研究概览
简要总结
A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced or metastatic pretreated NSCLC
- •Measurable disease
- •Adequate hematologic, hepatic and renal functions.
- •ECOG Performance Status 0-2
排除标准
- •Inability to swallow capsules
- •Recent significant cardiovascular disease
- •Women who are pregnant or breastfeeding
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung CancerNon-Small-Cell Lung CancerLung CancerNSCLCNCT00297089AbbVie (prior sponsor, Abbott)165
已完成
不适用
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.PER-030-02ELI LILLY INTERAMERICA INC.,
进行中（未招募）
不适用
A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer(Sweden will participate in Phase 2 of this trial, only)platinum sensitive recurrent ovarian or primary peritoneal cancerMedDRA version: 8.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSEUCTR2004-002782-20-SEEli Lilly and Company Limited85
进行中（未招募）
不适用
A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal CancerEUCTR2004-002782-20-DEEli Lilly and Company Limited110
Unknown
2 期
Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid CancerThyroid CancerNCT00786552University Hospital Schleswig-Holstein47